These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35094397)

  • 1. Serious health threat of mucormycosis during the ongoing COVID-19 pandemic: what dermatologists need to know in this regard.
    Hatami P; Balighi K; Nicknam Asl H; Aryanian Z
    Int J Dermatol; 2022 Aug; 61(8):979-981. PubMed ID: 35094397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucormycosis: An unanticipated progeny of COVID-19.
    Shrestha GS; Bhandari S; Lamsal R; Gurung U
    JNMA J Nepal Med Assoc; 2021 Sep; 59(241):965-967. PubMed ID: 35199723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
    Singh AK; Singh R; Joshi SR; Misra A
    Diabetes Metab Syndr; 2021; 15(4):102146. PubMed ID: 34192610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
    Rudrabhatla PK; Reghukumar A; Thomas SV
    Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 and mucormycosis superinfection: the perfect storm.
    Al-Tawfiq JA; Alhumaid S; Alshukairi AN; Temsah MH; Barry M; Al Mutair A; Rabaan AA; Al-Omari A; Tirupathi R; AlQahtani M; AlBahrani S; Dhama K
    Infection; 2021 Oct; 49(5):833-853. PubMed ID: 34302291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of cutaneous mucormycosis associated with COVID-19: A perspective from Pakistan.
    Asri S; Akram MR; Hasan MM; Asad Khan FM; Hashmi N; Wajid F; Ullah I
    Int J Health Plann Manage; 2022 Mar; 37(2):1157-1159. PubMed ID: 34476830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India.
    Rocha ICN; Hasan MM; Goyal S; Patel T; Jain S; Ghosh A; Cedeño TDD
    Trop Med Int Health; 2021 Sep; 26(9):1016-1018. PubMed ID: 34117677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucormycosis-A serious threat in the COVID-19 pandemic?
    Szarpak L; Chirico F; Pruc M; Szarpak L; Dzieciatkowski T; Rafique Z
    J Infect; 2021 Aug; 83(2):237-279. PubMed ID: 34029629
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of the COVID-19 pandemic on the diagnosis and treatment of skin cancers, a mini review.
    Aryanian Z; Balighi K; Goodarzi A; Sadeghi Nia A; Afshar ZM; Hatami P
    Cancer Rep (Hoboken); 2023 Sep; 6(9):e1854. PubMed ID: 37434543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rampant Increase in Cases of Mucormycosis in India and Pakistan: A Serious Cause for Concern during the Ongoing COVID-19 Pandemic.
    Ghazi BK; Rackimuthu S; Wara UU; Mohan A; Khawaja UA; Ahmad S; Ahmad S; Hasan MM; Dos Santos Costa AC; Ahmad S; Essar MY
    Am J Trop Med Hyg; 2021 Aug; 105(5):1144-1147. PubMed ID: 34460426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.
    Hatami P; Balighi K; Nicknam Asl H; Aryanian Z
    Dermatol Ther; 2022 Jan; 35(1):e15216. PubMed ID: 34811862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covid-19 and mucormycosis (Black Fungus): An epidemic within the pandemic.
    Gambhir RS; Aggarwal A; Bhardwaj A; Kaur A; Sohi RK; Mehta S
    Rocz Panstw Zakl Hig; 2021; 72(3):239-244. PubMed ID: 34553877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucormycosis in COVID-19 patients.
    Sundaram N; Bhende T; Yashwant R; Jadhav S; Jain A
    Indian J Ophthalmol; 2021 Dec; 69(12):3728-3733. PubMed ID: 34827032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19-associated mucormycosis: An updated systematic review of literature.
    Pal R; Singh B; Bhadada SK; Banerjee M; Bhogal RS; Hage N; Kumar A
    Mycoses; 2021 Dec; 64(12):1452-1459. PubMed ID: 34133798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
    Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
    J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucormycosis in COVID-19 recovered patients.
    Kumar A
    J Med Virol; 2022 Apr; 94(4):1272-1273. PubMed ID: 34905224
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
    Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
    Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspergillosis and Mucormycosis in COVID-19 Patients: A Systematic Review.
    Afzal S; Nasir M
    J Coll Physicians Surg Pak; 2022 May; 32(5):639-645. PubMed ID: 35546702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.
    Gupta G; S R; Singh Y; Thangavelu L; Singh SK; Dureja H; Chellappan DK; Dua K
    Drug Dev Res; 2021 Nov; 82(7):880-882. PubMed ID: 34323298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.